Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

NCT01258933 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Leukemia
Lymphoma

Interventions

DRUG: Ofatumumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]